Chemoradiation with adaptive brachytherapy for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of pelvic chemoradiation (chemotherapy and radiation) with a special type of brachytherapy (internal radiation) that adjusts the dose during treatment for locally advanced cervical cancer. It aims to improve tumor control while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread locally but not to distant organs
- You have not had radiation therapy to your belly or pelvic area before
- You are between 18 and 75 years old
- You are able to take care of yourself (performance status 0-2)
- Your heart, liver, kidneys, and blood counts are within acceptable ranges
- You are not pregnant or nursing, and will use contraception if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests whether using CT scans (instead of MRIs) to guide internal radiation for cervical cancer works just as well. If you are getting standard chemoradiation plus brachytherapy, you may be able to join with fewer scans.
This trial tests a type of radiation that adapts to your body changes during treatment for cervical cancer. It aims to improve accuracy and reduce side effects.
This trial tests a shorter, personalized radiation schedule for cervical cancer. It uses daily CT scans to adjust the radiation beam for better targeting. It may mean fewer hospital visits and less damage to healthy tissue.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a new way of delivering radiation therapy (brachytherapy) combined with chemotherapy for advanced cervical cancer. The goal is to see if a faster, more intense radiation schedule is safe and effective.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.